Inam S. Arif
Al Mustansiriyah University, College of Pharmacy, Baghdad/Iraq
Diabetic cardiomyopathy (DCM) is characterized by functional and structural dysregulation in which hyperglycemia is the main factor involved in DCM pathogenesis.
Rats were divided into 6 group: control group, non-diabetic rats with rosiglitazone (3 mg/kg/day), non-diabetic rats with sitagliptin (20 mg/kg/day), diabetic rats (alloxan 70 mg/kg IP injection), diabetic rats treated with rosiglitazone (3 mg/kg/day), diabetic rats treated with sitagliptin (20 mg/kg /day). Each diabetic rat was left for 1 month and then was given the specified doses of drugs for 1 month; the mortality rate was 50%.
The results showed that sitagliptin in DM group significantly decreased serum level of glucose, cholesterol, LDL, creatine kinase-MB compared to DM group and increased serum adiponectin level compared to DM group. On the other hand, rosiglitazone did not show significant changes on these parameters although reduction in serum glucose level was observed.
According to the results and the conditions of this work, treatment with sitagliptin showed more valuable effect than treatment with rosiglitazone in the prevention of cardiovascular complication by reducing serum levels of cholesterol, LDL, increasing serum level of adiponectin and decreasing damage of cardiomyocyte, which can be correlated to the decrease in serum creatine kinase-MB level.